Some of you might know that Pfizer acquired Anacor's Eucrisa for $5.2B last year. I'm surprised to read that no new eczema drugs were approved in the past 15 years.
"In the past 15 years, there have been no new molecules approved for eczema - or atopic dermatitis - a common, relapsing, inflammatory skin disorder that affects 18-25 million people in the United States."
https://www.reuters.com/article/us-anacor-pha...SKCN0Y7143
Eucrisa's bar wasn't set very high for approval.
"The primary efficacy endpoint was met, with success in Investigator’s Static Global Assessment (ISGA) defined as the proportion of patients achieving an ISGA score or zero or one with at least a two-grade improvement from baseline. Eucrisa-treated patients achieved statistically significant results compared with vehicle at day 29 (Trial 1: 32.8% vs. 25.4%, p = 0.038; Trial 2: 31.4% vs. 18.0%, p < 0.001). These findings mark a substantial turning point for this disease area by offering a novel and efficacious alternative to existing therapies."
http://www.drugdevelopment-technology.com/res...s-5710273/
More on B and Eucrisa.
"The human skin microbiome is influenced by bacterial infection in a complex manner. It has been hypothesized that increased susceptibility of people with atopic dermatitis to S. aureus infections, which is significantly over-expressed in this skin condition, may arise from the impaired expression of Host Defense Proteins (HDPs). And unlike Crisaborole, which was acquired in 2016 by Pfizer for $5.2 billion, Brilacidin, is highly active against S. aureus. Brilacidin might show another distinct advantage in that the drug candidate exhibits a strong inhibitory effect on IL-1, whereas Crisaborole shows no such activity. (IL-1 is linked to the pathogenesis of numerous diseases, including rheumatic disease and eczema.)"
http://www.ipharminc.com/new-blog/2017/6/5/br...ermatology
"In the past 15 years, there have been no new molecules approved for eczema - or atopic dermatitis - a common, relapsing, inflammatory skin disorder that affects 18-25 million people in the United States."
https://www.reuters.com/article/us-anacor-pha...SKCN0Y7143
Eucrisa's bar wasn't set very high for approval.
"The primary efficacy endpoint was met, with success in Investigator’s Static Global Assessment (ISGA) defined as the proportion of patients achieving an ISGA score or zero or one with at least a two-grade improvement from baseline. Eucrisa-treated patients achieved statistically significant results compared with vehicle at day 29 (Trial 1: 32.8% vs. 25.4%, p = 0.038; Trial 2: 31.4% vs. 18.0%, p < 0.001). These findings mark a substantial turning point for this disease area by offering a novel and efficacious alternative to existing therapies."
http://www.drugdevelopment-technology.com/res...s-5710273/
More on B and Eucrisa.
"The human skin microbiome is influenced by bacterial infection in a complex manner. It has been hypothesized that increased susceptibility of people with atopic dermatitis to S. aureus infections, which is significantly over-expressed in this skin condition, may arise from the impaired expression of Host Defense Proteins (HDPs). And unlike Crisaborole, which was acquired in 2016 by Pfizer for $5.2 billion, Brilacidin, is highly active against S. aureus. Brilacidin might show another distinct advantage in that the drug candidate exhibits a strong inhibitory effect on IL-1, whereas Crisaborole shows no such activity. (IL-1 is linked to the pathogenesis of numerous diseases, including rheumatic disease and eczema.)"
http://www.ipharminc.com/new-blog/2017/6/5/br...ermatology
2
Innovation Pharmaceuticals Inc (IPIX) Stock Research Links
